Pharmaphorum
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Pharmaphorum
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Pharmaphorum
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.